Search

Although Lloviu virus (LLOV) was discovered in the carcasses of insectivorous Schreiber’s Bent-winged bats in the caves of Northern Spain in 2002, its infectivity and pathogenicity remain unclear. We examined the seroprevalence of LLOV in potentially exposed Schreiber’s Bent-winged bats (n = 60), common serotine bats (n = 10) as controls, and humans (n = 22) using an immunoblot assay. We found antibodies against LLOV GP2 in all of Schreiber’s Bent-winged bats serum pools, but not in any of the common serotine bats and human pools tested. To confirm this seroreactivity, 52 serums were individually tested using Domain Programmable Arrays (DPA), a phage display based-system serology technique for profiling filovirus epitopes. A serological signature against different LLOV proteins was obtained in 19/52 samples tested (36.5%). The immunodominant response was in the majority specific to LLOV-unique epitopes, confirming that the serological response detected was to LLOV. To our knowledge, this is the first serological evidence of LLOV exposure in live captured Schreiber’s Bent-winged bats, dissociating LLOV circulation as the cause of the previously reported die-offs.

Chronic kidney disease (CKD) is a growing global public health challenge worldwide. In Mexico, CKD prevalence is alarmingly high and remains a leading cause of morbidity and mortality. Diabetic kidney disease (DKD), a severe complication of diabetes, is a leading determinant of CKD. The escalating diabetes prevalence and the complex regional landscape in Mexico underscore the pressing need for tailored strategies to reduce the burden of CKD. This narrative review, endorsed by the Mexican College of Nephrologists, aims to provide a brief overview and specific strategies for healthcare providers regarding preventing, screening, and treating CKD in patients living with diabetes in all care settings. The key topics covered in this review include the main cardiometabolic contributors of DKD (overweight/obesity, hyperglycemia, arterial hypertension, and dyslipidemia), the identification of kidney-related damage markers, and the benefit of novel pharmacological approaches based on Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA). We also address the potential use of novel therapies based on Mineralocorticoid Receptor Antagonists (MRAs) and their future implications. Emphasizing the importance of multidisciplinary treatment, this narrative review aims to promote strategies that may be useful to alleviate the burden of DKD and its associated complications. It underscores the critical role of healthcare providers and advocates for collaborative efforts to enhance the quality of life for millions of patients affected by DKD.

Resumen: Introducción y objetivo: La epidemia de SARS-CoV-2 representa un riesgo especial para los pacientes en hemodiálisis (HD) por sus comorbilidades, y el cursar con una inflamación más severa con menos síntomas y peor evolución. Nuestro objetivo fue conocer las características clínicas y bioquímicas de los pacientes en hemodiálisis (HD) que presentaron cuadro sospechoso de COVID-19 (por sus siglas en inglés de Corona Virus Disease – 2019), sus factores de riesgo y desenlace. Material y métodos: Estudio de reporte de casos, retrospectivo, observacional, en los pacientes en HD sospechosos de COVID-19. Registrándose comorbilidades, clínica, laboratorio, prueba de transcripción reversa cuantitativa de la reacción en cadena de polimerasa (RT-qPCR) para SARS-COV-2 y desenlace. Se realizó estadística descriptiva y análisis de regresión lineal y logístico. Resultados: De 1.514 personas que recibían tratamiento de HD, 248 pacientes presentaron sintomatología sospechosa de COVID-19 (106 positivos, 83 negativos y 59 sospechosos por PCR), mediana de edad de 51 años (RI 36-63 años), 54,8% masculinos, hipertensión (87,5%), hemoglobina de 8,9 g (RI 7,5-10,6 g); la sintomatología de tos, fiebre y disnea (65,7, 64,5 y 53,2% respectivamente). El porcentaje de letalidad en el grupo de los pacientes con RT-qPCR positiva fue de 29,24%. Conclusiones: La tasa de mortalidad y letalidad es alta en este tipo de población. El grupo etario, el sexo y las comorbilidades cardiometabólicas se comportan similar al resto de la población no renal. El estado bioquímico preexistente no marca una diferencia en el desenlace. La sintomatología predominante es respiratoria. Abstract: Introduction and objective: The SARS-CoV-2 epidemic represents a special risk for patients on hemodialysis (HD) due to their comorbidities and the fact that they often have a more severe case of inflammation with fewer symptoms and a worse evolution and outcome. The aim of this study was to detect the clinical and biochemical characteristics of patients on hemodialysis (HD) who presented a suspicious involvement of COVID-19 (Corona Virus Disease – 2019), their risk factors and specific outcomes. Material and methods: This is a retrospective, observational case report study in HD patients suspected of having COVID-19. Records pointed to comorbidities, clinical and laboratory tests, quantitative reverse transcription polymerase chain reaction (RT-qPCR) tests for SARS-COV-2 and outcomes. Descriptive statistics and linear and logistic regression analyses were performed. Results: Of the total number of HD patients (1514), 248 HD patients were suspected to have COVID-19 (106 were positive, 83 were negative and 59 suspected using PCR testing); the median age was 51 years (IR 36-63 years), 54.8% were males, had hypertension (87.5%), with a hemoglobin count of 8.9 g (IR 7.5-10.6 g) and symptoms such as cough, fever and dyspnea (65.7, 64.5 and 53.2%, respectively). The fatality rate in the group of patients with positive RT-qPCR was 29.24%. Conclusions: The mortality and fatality rate is often high in this population. The age group, sex, and cardio-metabolic comorbidities behave similarly to the rest of the non-renal population. Pre-existing biochemical status does not make a difference in the outcome. The predominant symptomatology was pulmonary in nature.